Samsung Biologics to provide CDMO support for ‘bio-venture’ firm GI Innovation

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Manjurul)
(Image: Getty/Manjurul)

Related tags: Samsung biologics, GI Innovation, CDMO, Cell line development, phase I

Samsung Biologics is providing contract development services for GI Innovation’s pipeline, with the first among five molecules to initiate development immediately, says company representative.

The companies last week signed the contract for immune-chemotherapy at the Samsung Biologics headquarters in Seoul, South Korea.

Also headquartered in Seoul, GI Innovation – described as “bio-venture company” – is developing new drugs through the combination of microbiome and protein drugs, according to the company.

1
Samsung BioLogics CEO Tae Han Kim and GI Innovation CEO Soo Yeon Nam.

This is the second contract GI Innovation has signed with Samsung Biologics since launching their first project with together in June of last year, according to a Samsung Biologics representative.

The agreement is part of a multi-project deal that will see Samsung Biologics provide a range of services including cell line, process, and analytical method development. The company also will manufacture materials for the Phase I clinical trial and will support IND filing support for GI’s drug pipeline.

“Through the partnership, the first among five molecules will initiate development immediately, and overall SBL [Samsung Biologics] will develop two of GI’s projects per year,”​ the representative explained.

GI Innovation CEO Soo Yeon Nam said in a press release: "Thanks to Samsung BioLogics' CDMO business, we can overcome the problem of producing high-quality clinical test samples, the biggest barrier of bio venture companies.

"We are very positive that global pharmaceutical companies interested in the R&D pipeline of GI Innovation will be able to access global new drug licensing (BLA) and biotech drug business through Samsung BioLogics' CDMO service,”​ she added. “Through this collaboration, we wish to demonstrate the win-win model of venture firms and large corporations that the people and the government want."

‘One-stop service’

According to the Samsung Biologics representative, “The number of biotech companies focused on R&D discovery of novel biologics are constantly increasing in the market, and thus the need to outsource development services is growing rapidly.”

The company launched its contract development business in 2018 and has since secured new projects with eight domestic and overseas companies, including GI Innovation, the representative explained, citing its ability to provide “one-stop service” as one of the greatest benefits to working with the company.

“Altogether, our strength is providing integrated biologics development and manufacturing services at one-site, as a true one-stop service provider,” ​they said.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars